World Respiratory Collaboration and Licensing Deals Trends Analysis Report and Directory 2023

Dublin, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The "Respiratory Collaboration and Licensing Deals 2016-2023" report has been added to * ResearchAndMarkets.com's* offering.

"Respiratory Collaboration and Licensing Deals" offers an in-depth understanding and unprecedented access to the respiratory deals made by the world's leading biopharmaceutical companies.

This report, which has been fully revised and updated, provides comprehensive details of respiratory deals spanning from 2016 to 2023. It also grants access to the payment terms disclosed in these deals, offering valuable insights into various aspects of the agreements.

Understanding the flexibility embedded in the negotiated deal terms of potential partners is crucial in gauging the negotiation process's potential outcomes. While smaller companies may seek payment details, the devil often lies in the finer points, such as payment triggers and rights transfer, which contract documents can illuminate, unlike press releases and databases.

The report features a comprehensive listing of collaboration and licensing deals announced since 2016, sourced from the Current Agreements deals and alliances database. Financial terms, when available, are included, along with links to the actual licensing contract documents submitted to the Securities Exchange Commission by the companies and their partners.

The initial chapters provide an orientation to respiratory dealmaking and business activities. Chapter 1 serves as an introduction to the report, while Chapter 2 delves into an analysis of the trends in respiratory dealmaking.

Chapter 3 focuses on the financial deal terms for respiratory deals with announced development stages. The deals are categorized based on headline value, upfront payments, milestone payments, and royalty rates.

Chapter 4 presents a review of the top 25 most active biopharma companies engaged in respiratory dealmaking. For deals with publicly available agreement contracts, links are provided for online access through the Current Agreements deals and alliances database.

Chapter 5 offers a comprehensive and detailed review of respiratory deals announced since 2016, complete with links to online versions of the actual contract documents for each deal title, ensuring easy access.

Chapter 6 provides a comprehensive directory of respiratory deals categorized by therapeutic target.

The report further includes numerous tables and figures that visually illustrate trends and activities in respiratory dealmaking since 2016. Additionally, it features a comprehensive deal directory organized alphabetically by company and technology type. Each deal title includes a Weblink for online access to the deal record and, when available, the contract document, facilitating easy retrieval of detailed information.

*Key benefits*

*Respiratory Collaboration and Licensing Deals provides the reader with the following key benefits:*

· Understand deal trends since 2016
· Browse respiratory collaboration and licensing deals
· Benchmark analysis - identify market value of transactions
· Financials terms - upfront, milestone, royalties
· Directory of deals by company A-Z, therapy focus and technology type
· Leading deals by value
· Most active dealmakers
· Identify assets and deal terms for each transaction
· Access contract documents - insights into deal structures
· Due diligence - assess suitability of your proposed deal terms for partner companies
· Save hundreds of hours of research time

*Respiratory Collaboration and Licensing Deals includes:*

· Trends in respiratory dealmaking in the biopharma industry
· Overview of collaboration and licensing deal structure
· Directory of respiratory deal records covering pharmaceutical and biotechnology
· The leading respiratory deals by value
· Most active respiratory licensing dealmakers

*In Respiratory Collaboration and Licensing Deals, the available deals are listed by:*

· Company A-Z
· Headline value
· Therapeutic area
· Technology type

*Analyzing contract agreements allows due diligence of:*

· What are the precise rights granted or optioned?
· What is actually granted by the agreement to the partner company?
· What exclusivity is granted?
· What is the payment structure for the deal?
· How are sales and payments audited?
· What is the deal term?
· How are the key terms of the agreement defined?
· How are IPRs handled and owned?
· Who is responsible for commercialization?
· Who is responsible for development, supply, and manufacture?
· How is confidentiality and publication managed?
· How are disputes to be resolved?
· Under what conditions can the deal be terminated?
· What happens when there is a change of ownership?
· What sublicensing and subcontracting provisions have been agreed?
· Which boilerplate clauses does the company insist upon?
· Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
· Which jurisdiction does the company insist upon for agreement law?

*Key Topics Covered:*

*Executive Summary*

*Chapter 1 - Introduction*

*Chapter 2 - Trends in respiratory dealmaking*
2.1. Introduction
2.2. Respiratory partnering over the years
2.3. Respiratory partnering by deal type
2.4. Respiratory partnering by industry sector
2.5. Respiratory partnering by stage of development
2.6. Respiratory partnering by technology type
2.7. Respiratory partnering by therapeutic indication

*Chapter 3 - Financial deal terms for respiratory partnering*
3.1. Introduction
3.2. Disclosed financials terms for respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates

*Chapter 4 - Leading respiratory deals and dealmakers*
4.1. Introduction
4.2. Most active in respiratory partnering
4.3. List of most active dealmakers in respiratory
4.4. Top respiratory deals by value

*Chapter 5 - Respiratory contract document directory*
5.1. Introduction
5.2. Respiratory partnering deals where contract document available

*Chapter 6 - Respiratory dealmaking by therapeutic target*
6.1. Introduction
6.2. Deals by respiratory therapeutic target

*Deal Directory*
Deal directory - Respiratory deals by company A-Z 2016 to 2023
Deal directory - Respiratory deals by technology type 2016 to 2023
Deal type definitions

*Companies Mentioned*

· Alnylam Pharmaceuticals
· Vortran Medical
· Sichuan University
· Lung and Blood Institute
· Food and Drug Administration (FDA)
· Bill and Melinda Gates Foundation
· Zhejiang Medicine
· Jubilant DraxImage
· Enzyvant Science
· Altavant Sciences
· Biostar Pharmaceuticals
· Scholar Rock
· Monopar Therapeutics
· Wockhardt
· Innovare
· Celularity
· Highmark Blue Shield
· Highmark Health
· Glenmark Pharmaceuticals
· 4D Pharma
· BESPharma
· IR Pharma
· SI Pharmaceuticals
· Wal-Mart
· Sanovas
· Amyndas Pharmaceuticals
· Tunitas Therapeutics
· Innovata HK
· Medidata Solutions
· Advocate Health Care
· Innovate UK
· Foundation for Sarcoidosis Research
· Simulations Plus
· Innovative Genomics Initiative (IGI)
· Innovative Medicines Initiative (IMI)
· Laboratory Corporation of America
· Novavax
· Dynavax Technologies
· Pharmaxis
· Scarab Genomics
· Punjab Province

For more information about this report visit https://www.researchandmarkets.com/r/y6lsbf

*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900